Novo Nordisk to present advances in diabetes treatment

(CercleFinance.com) - Novo Nordisk announces the presentation of 21 abstracts (7 oral and 14 short) at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), to be held September 9-13, 2024 in Madrid.


Data will also be presented at scientific symposia on the COMBINE program with IcoSema for type 2 diabetes, the FLOW trial on the effects of semaglutide 1 mg on the kidneys, and amylin treatment for metabolic diseases.

"This year, we are highlighting new data from our pipeline and our portfolio in diabetes, obesity, cardiovascular and renal diseases, where we continue to push the boundaries with the aim of advancing treatments to help more patients," said Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk.

Copyright (c) 2024 CercleFinance.com. All rights reserved.